Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Cardiovascular Systems is a medical devices business based in the US. Cardiovascular Systems stocks (CSII.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $42.74 – a decrease of 2.07% over the previous week. Cardiovascular Systems employs 780 staff and has a trailing 12-month revenue of around $244.7 million.
Finder's Pick for
Beginners
Finder's Pick for
Free Trades
Finder's Pick for
Commodity Stocks
Finder's Pick for
Global Trading
| Latest market close | $15.61 |
|---|---|
| 52-week range | $14.12 - $44.57 |
| 50-day moving average | $19.65 |
| 200-day moving average | $24.98 |
| Wall St. target price | $22.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.84 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $15.61 from 2022-05-20
| 1 week (2022-05-11) | N/A |
|---|---|
| 1 month (2022-04-20) | -28.53% |
| 3 months (2022-02-18) | -17.06% |
| 6 months (2021-11-22) | -34.77% |
| 1 year (2021-05-21) | -59.49% |
|---|---|
| 2 years (2020-05-22) | -57.82% |
| 3 years (2019-05-22) | 39.64 |
| 5 years (2017-05-22) | 31.61 |
Valuing Cardiovascular Systems stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cardiovascular Systems's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cardiovascular Systems's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 177.27. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Cardiovascular Systems's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Cardiovascular Systems's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.6 million.
The EBITDA is a measure of a Cardiovascular Systems's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $244.7 million |
|---|---|
| Gross profit TTM | $197.8 million |
| Return on assets TTM | -5.82% |
| Return on equity TTM | -12.42% |
| Profit margin | -13.29% |
| Book value | $6.22 |
| Market capitalisation | $601.2 million |
TTM: trailing 12 months
We're not expecting Cardiovascular Systems to pay a dividend over the next 12 months.
Cardiovascular Systems's shares were split on a 1:10 basis on 26 February 2009. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cardiovascular Systems shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cardiovascular Systems shares which in turn could have impacted Cardiovascular Systems's share price.
Over the last 12 months, Cardiovascular Systems's shares have ranged in value from as little as $14.12 up to $44.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cardiovascular Systems's is 0.9054. This would suggest that Cardiovascular Systems's shares are less volatile than average (for this exchange).
Cardiovascular Systems, Inc. , a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc.
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Read more…
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.
Read more…Learn more about apps like Wealthsimple to find the best trading platform for your unique set of needs.
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Steps to owning and managing ENT stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KAMBI stock, with 24-hour and historical pricing before you buy.
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Steps to owning and managing RSI stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTHF stock, with 24-hour and historical pricing before you buy.
Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
